Trainings and Resources

Start your journey to better mental health today and find your support system on FindSupport.gov. Let’s honor the memories of those we have lost and prevent others from managing their mental health challenges alone. If you or someone you know is in a mental health crisis, Text or call 988 or chat 988lifeline.org for free, confidential support 24/7

More than 450 clinicians and counselors in rural New England were surveyed about stigma as a barrier to treating patients for opioid used disorder (OUD) as well as practitioners’ beliefs about medications for OUD.  Over half (55 percent) ranked stigma as the highest barrier among other factors such as time and staffing, medication diversion, and organizational/clinic barriers.

Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.

The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment. 

The National Institute of Mental Health (NIMH) provides several behavioral warning signs and symptoms you can look out for in children and youth. While certain behavior can be a part of growing up, the warning signs and symptoms listed by the NIMH may be a reason to contact a health professional. Mental illnesses can be treated and talking with your child or teen can help you identify when to see a health professional.

In response to a record 38,000 comments from the public, the Substance Abuse and Mental Health Services Administration and the Drug Enforcement Agency will extend the full set of telemedicine flexibilities adopted during the COVID-19 public health emergency that ended, May 11. The temporary rule will allow providers to prescribe controlled medications, such as buprenorphine for opioid use disorder (OUD), via telemedicine until November 11, 2023.

Public Health Institute's (PHI) Cherished Futures for Black Moms and Babies Program is such an important program and example. Racism and toxic stress are root causes for racial disparities in birth outcomes. PHI’s Cherished Futures for Black Moms and Babies is centering the lived experiences of Black women and birthing parents to address this ongoing maternal mortality crisis, bringing together decision-makers from local hospitals, public health departments, health plans and Black women community leaders to identify and put into action systems-change solutions at clinical, institutional and community levels.

Illuminate Colorado, an RCORP Neonatal Abstinence Syndrome (NAS) grantee, and partners presented on their Tough as a Mother campaign. Tough as a Mother is a statewide campaign launched in May 2020 and has been working to decrease the stigma around maternal substance use disorder. The Illuminate Colorado Team provided an overview of their campaign and how others can access the shared resources, followed by time for Q&A.

Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.

The Policy Center for Maternal Mental Health, in collaboration with the George Washington University, released the first-ever grading of state efforts in addressing maternal mental health. The U.S. received a D, and 42 states received Ds and Fs.